Literature DB >> 17430687

Pancreatic cancer: an update.

Hedy Lee Kindler1.   

Abstract

Pancreatic cancer is refractory to most chemotherapy. For many years, the only active agent for this disease was gemcitabine, which has very modest activity. Two new regimens, gemcitabine plus erlotinib and gemcitabine plus capecitabine, have recently demonstrated statistically significant survival improvements compared with single-agent gemcitabine. Several key negative studies have also been reported recently. This review discusses recent trials that have changed the standard of care for patients with advanced pancreatic cancer.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17430687     DOI： 10.1007/s11912-007-0018-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  27 in total

1.  High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma.

Authors:  Y Seo; H Baba; T Fukuda; M Takashima; K Sugimachi
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

2.  A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

Authors:  H Oettle; D Richards; R K Ramanathan; J L van Laethem; M Peeters; M Fuchs; A Zimmermann; W John; D Von Hoff; M Arning; H L Kindler
Journal:  Ann Oncol       Date:  2005-08-08       Impact factor: 32.976

3.  Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.

Authors:  Tomislav Dragovich; Mark Huberman; Daniel D Von Hoff; Eric K Rowinsky; Paul Nadler; Debra Wood; Marta Hamilton; George Hage; Julie Wolf; Amita Patnaik
Journal:  Cancer Chemother Pharmacol       Date:  2006-12-06       Impact factor: 3.333

4.  Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Authors:  Ghassan K Abou-Alfa; Richard Letourneau; Graydon Harker; Manuel Modiano; Herbert Hurwitz; Nerses Simon Tchekmedyian; Kevie Feit; Judie Ackerman; Robert L De Jager; S Gail Eckhardt; Eileen M O'Reilly
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

5.  Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.

Authors:  Heike Immervoll; Dag Hoem; Kalaiarasy Kugarajh; Solrun J Steine; Anders Molven
Journal:  Virchows Arch       Date:  2006-04-06       Impact factor: 4.064

6.  Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis.

Authors:  Kosuke Tobita; Hiroshi Kijima; Shoichi Dowaki; Hiroyuki Kashiwagi; Yasuo Ohtani; Yasuhisa Oida; Hitoshi Yamazaki; Masato Nakamura; Yoshito Ueyama; Makiko Tanaka; Sadaki Inokuchi; Hiroyasu Makuuchi
Journal:  Int J Mol Med       Date:  2003-03       Impact factor: 4.101

7.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Authors:  Jordan D Berlin; Paul Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al Bowen Benson
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

8.  Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

Authors:  Margaret Tempero; William Plunkett; Veronique Ruiz Van Haperen; John Hainsworth; Howard Hochster; Renato Lenzi; James Abbruzzese
Journal:  J Clin Oncol       Date:  2003-07-28       Impact factor: 44.544

9.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Authors:  Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

10.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Authors:  J L Abbruzzese; R Grunewald; E A Weeks; D Gravel; T Adams; B Nowak; S Mineishi; P Tarassoff; W Satterlee; M N Raber
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544
View more
  17 in total

1.  (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.

Authors:  Nemil Shah; Guihua Zhai; Joseph A Knowles; Cecil R Stockard; William E Grizzle; Naomi Fineberg; Tong Zhou; Kurt R Zinn; Eben L Rosenthal; Hyunki Kim
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

Review 2.  Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.

Authors:  Jonathan Welti; Sonja Loges; Stefanie Dimmeler; Peter Carmeliet
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

3.  Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.

Authors:  Mike Mattie; Ashley Christensen; Mi Sook Chang; William Yeh; Suzanne Said; Yuriy Shostak; Linnette Capo; Alla Verlinsky; Zili An; Ingrid Joseph; Yi Zhang; Sathish Kumar-Ganesan; Karen Morrison; David Stover; Pia Challita-Eid
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

4.  The way forward in treating pancreatic cancer.

Authors:  Valeriy Sedov; Elizabeth Poplin
Journal:  Ther Adv Med Oncol       Date:  2010-05       Impact factor: 8.168

5.  Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.

Authors:  Sonja Loges; Thomas Schmidt; Peter Carmeliet
Journal:  Genes Cancer       Date:  2010-01

6.  Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.

Authors:  Yong Gao; Zhiliang Jia; Xiangyu Kong; Qiang Li; David Z Chang; Daoyan Wei; Xiangdong Le; Huang Suyun; Shengdong Huang; Liwei Wang; Keping Xie
Journal:  Cancer Res       Date:  2011-06-14       Impact factor: 12.701

Review 7.  Autophagy as a mechanism for anti-angiogenic therapy resistance.

Authors:  Ankush Chandra; Jonathan Rick; Garima Yagnik; Manish K Aghi
Journal:  Semin Cancer Biol       Date:  2019-08-28       Impact factor: 15.707

8.  Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening.

Authors:  Sandra Pérez-Torras; Anna Vidal-Pla; Rosa Miquel; Vanessa Almendro; Laureano Fernández-Cruz; Salvador Navarro; Joan Maurel; Neus Carbó; Pere Gascón; Adela Mazo
Journal:  Cell Oncol (Dordr)       Date:  2011-06-17       Impact factor: 6.730

9.  Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer.

Authors:  Lei Li; Yiqi Du; Xiangyu Kong; Zhaoshen Li; Zhiliang Jia; Jiujie Cui; Jun Gao; Guokun Wang; Keping Xie
Journal:  Clin Cancer Res       Date:  2013-07-15       Impact factor: 12.531

10.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Authors:  Zhiliang Jia; Yong Gao; Liwei Wang; Qiang Li; Jun Zhang; Xiangdong Le; Daoyan Wei; James C Yao; David Z Chang; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.